What Ozempic Gastroparesis Records Reveal About Risks in Arizona

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Inquiry

If you or someone you know has experienced severe stomach issues while taking Ozempic, you may be concerned about gastroparesis. Recent records and FDA adverse event reports have brought attention to this potential risk in Arizona and beyond. Building on a foundation of medical and legal information, this page examines the available data and what it means for patients.

Find Out If You Qualify for Compensation →

The Medical Reality: Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules. The overlap between Ozempic’s known gastrointestinal effects and gastroparesis symptoms raises questions about causation and adequate warnings. Evidence from clinical trials shows that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal reactions reported at frequencies below 5% include dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which aligns with the mechanistic pathway of delayed gastric emptying.

Mechanistic Link and Warning Adequacy

The mechanistic link between Ozempic and gastroparesis involves GLP-1 receptor activation, which inhibits gastric motility and slows gastric emptying. This effect is intended for glycemic control but can become pathological in susceptible individuals, leading to gastroparesis. The timeline between exposure and documented harm varies; symptoms often emerge during dose escalation, as noted in clinical trials where most nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, chronic use may lead to persistent gastroparesis even after drug discontinuation, complicating the temporal relationship. Regarding adequacy of warnings, the prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a distinct warning. The label includes a section on hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis is not separately highlighted, potentially leaving patients and healthcare providers unaware of the risk. This gap in warning may be relevant for legal considerations, as patients who develop gastroparesis after using Ozempic might argue that the manufacturer failed to adequately communicate the risk.

Legal Considerations for Arizona Patients

For affected patients in Arizona, attorney-related considerations include the statute of limitations for product liability claims. In Arizona, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For claims involving inadequate warnings, the timeline may start when the patient became aware of the link between Ozempic and gastroparesis. Given that gastroparesis symptoms can mimic common gastrointestinal issues, patients may not immediately associate them with Ozempic, potentially extending the discovery period. Legal counsel can help determine the applicable deadline based on individual circumstances. The timeline between exposure and documented harm is critical for establishing causation. Clinical trial data show that gastrointestinal adverse reactions, including those that could indicate gastroparesis, often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, some patients may develop symptoms after prolonged use. Medical records documenting the onset of symptoms relative to Ozempic initiation are essential for building a case. Additionally, diagnostic confirmation of gastroparesis through gastric emptying studies can strengthen the link. In summary, Ozempic use is associated with a higher incidence of gastrointestinal adverse reactions, including those consistent with gastroparesis. The mechanistic pathway of delayed gastric emptying supports a plausible link. The adequacy of warnings is questionable, as gastroparesis is not explicitly listed. For Arizona patients, the statute of limitations requires prompt legal evaluation. Evidence from clinical trials and prescribing information provides a foundation for understanding the risks and potential legal recourse.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Arizona?

In Arizona, the statute of limitations for personal injury claims, including product liability, is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, the clock may start when you became aware of the link between the drug and your condition. It is crucial to consult an attorney promptly to determine your specific deadline.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to gastrointestinal symptoms. While clinical trials show increased rates of nausea, vomiting, and other GI issues, gastroparesis is not explicitly listed as a warning. However, the mechanistic link and reported symptoms suggest a plausible association. Medical evidence, including gastric emptying studies, can help establish causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.